Empagliflozin
Dumping Syndrome
Insel Gruppe AG, University Hospital BernSmall moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Dumping Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cabergoline RECORDATI GROUP | Phase 4 | BB |
Pasireotide RECORDATI GROUP | Phase 4 | BB |
Exendin 9-39 Cambridge University Hospitals NHS Foundation Trust | N/A | D |
Anakinra University Hospital, Basel, Switzerland | N/A | D |
Rifaximin Cambridge University Hospitals NHS Foundation Trust | N/A | D |
View all 9 →
Same molecule, other indications
Empagliflozin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →